AU · rank #14 · 2026-07-24
DSFIR
AMSTERDAM · EUR · $22.64B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.621 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.03 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 4 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $85.54 | +6.1% |
| Momentum acceleration 3-month minus 12-month momentum. | +31.39% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.10 |
| Gross margin TTM | +39.1% |
| 52w high | $87.68 |
| Market cap (USD) | $22.64B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
DSM-Firmenich AG is a leading global consumer nutrition, health, and beauty company focused on high-margin specialty ingredients following the pending €2.2 billion divestment of its bulk Animal Nutrition & Health business.
Rationale
Positive analyst revision momentum (75% agreement and upward 30-day EPS revisions) signals strong fundamental support ahead of the July 30, 2026 earnings release, further bolstered by a €500 million share buyback program.
Material risks
- 1Macroeconomic margin pressure from rising freight and energy costs driven by Middle East tensions, which have already compressed recent adjusted EBITDA margins.
- 2Negative foreign exchange fluctuations that heavily impact reported sales figures, as seen in the 6% headwind during the first quarter of 2026.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.